美股异动|安进连涨三日稳定攀升政策压力下展现强劲上涨势头

Group 1 - Amgen's stock price increased by 3.00% on September 30, with a cumulative rise of 4.06% over three days, attracting market and investor attention [1] - The recent discussions surrounding Amgen are closely linked to the pressure from the Trump administration on drug pricing policies, which has impacted the entire pharmaceutical industry [1] - Despite concerns over policy uncertainties, Amgen's stock performance has continued to rise, supported by the easing of pressures on other major pharmaceutical companies [1] Group 2 - The pharmaceutical industry appears to be experiencing a reduction in policy pressures, providing a more stable operating environment for companies like Amgen to focus on innovative drug development [2] - Investors are advised to be cautious and consider policy risks and the company's ability to respond to uncertainties when investing in the pharmaceutical sector [2] - While Amgen has shown strong recent performance, it does not guarantee continuous stock price increases, necessitating a clear understanding of market volatility and strategic investment planning [2]